Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

INTRODUCTION: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Zhenggang, Ducreux, Michel, Abou-Alfa, Ghassan K., Merle, Philippe, Fang, Weijia, Edeline, Julien, Li, Zhiwei, Wu, Lihua, Assenat, Eric, Hu, Sheng, Rimassa, Lorenza, Zhang, Tao, Blanc, Jean-Frédéric, Pan, Hongming, Ross, Paul, Yen, Chia-Jui, Tran, Albert, Shao, Guoliang, Bouattour, Mohamed, Chen, Yajin, Meyer, Tim, Hou, Jinlin, Tougeron, David, Bai, Yuxian, Hou, Ming-Mo, Meng, Zhiqiang, Wu, John, Li, Vincent, Chica-Duque, Sandra, Cheng, Ann-Lii
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982342/
https://www.ncbi.nlm.nih.gov/pubmed/36872927
http://dx.doi.org/10.1159/000527175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982342/
https://www.ncbi.nlm.nih.gov/pubmed/36872927
http://dx.doi.org/10.1159/000527175

Ejemplares similares